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Abstract 
Background: Glioblastoma is the most common and malignant brain tumor in adults. Glioblastoma is usually fatal 
12–15 months after diagnosis and the current possibilities in therapy are mostly only palliative. Therefore, new forms 
of diagnosis and therapy are urgently needed. Since tumor‑associated macrophages are key players in tumor progres‑
sion and survival there is large potential in investigating their immunological characteristics in glioblastoma patients. 
Recent evidence shows the expression of variable immunoglobulins and TCRαβ in subpopulations of monocytes, 
in vitro polarized macrophages and macrophages in the tumor microenvironment. We set out to investigate the 
immunoglobulin sequences of circulating monocytes and tumor‑associated macrophages from glioblastoma 
patients to evaluate their potential as novel diagnostic or therapeutic targets.
Results: We routinely find consistent expression of immunoglobulins in tumor‑associated macrophages (TAM) and 
circulating monocytes from all glioblastoma patients analyzed in this study. However, the immunoglobulin repertoires 
of circulating monocytes and TAM are generally more restricted compared to B cells. Furthermore, the immunoglobu‑
lin expression in the macrophage populations negatively correlates with the tumor volume. Interestingly, the compar‑
ison of somatic mutations, V‑chain usage, CDR3‑length and the distribution of used heavy chain genes on the locus of 
chromosome 14 of the immunoglobulins from myeloid to B cells revealed virtually no differences.
Conclusions: The investigation of the immunoglobulin repertoires from TAM and circulating monocytes in glioblas‑
toma‑patients revealed a negative correlation to the tumor volume, which could not be detected in the immunoglob‑
ulin repertoires of the patients’ B lymphocytes. Furthermore, the immunoglobulin repertoires of monocytes were more 
diverse than the repertoires of the macrophages in the tumor microenvironment from the same patients suggesting a 
tumor‑specific immune response which could be advantageous for the use as diagnostic or therapeutic target.
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Background
Macrophages are omnipresent versatile immune cells 
with myeloid origin. Due to their function as phagocytes 
they are assigned to the innate immune system where 
they play a key role in chronic inflammation [1, 2].
Traditionally, the expression of combinatorial immune 
receptors represented by immunoglobulins (Ig) and T 
cell receptors (TCR) is thought to be an exclusive com-
petence of lymphoid effector cells like B and T cells [2, 
3]. However, in the past decade several publications pro-
vided evidence for the recombination of variable immune 
receptors in cells not belonging to the lymphoid line-
age [4, 5]. The initial observations by Puellmann et al. in 
2006 demonstrated the expression of variable αβ T cell 
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receptors in a subpopulation of neutrophil granulocytes 
[6–8]. Ensuing studies showed the recombination of TCR 
αβ/γδ in monocytes and macrophages [9, 10] as well as 
TCR γδ in eosinophils [11]. Interestingly, recent studies 
present the induction of TCRβ expression in neutrophils 
and macrophages during malaria infection [12, 13]. Fur-
thermore, an implication of these TCR based myeloid 
variable immune receptors in several chronic diseases 
like autoimmune disease [14], chronic periodontitis [15], 
tuberculosis [9] and atherosclerosis [16] was shown. 
Additionally, our laboratory demonstrated the recombi-
nation of variable TCRαβ by macrophages in the tumor 
microenvironment [17]. Importantly, most recent studies 
from our laboratory and others provided evidence for the 
expression of the second variable immune receptor based 
on immunoglobulin heavy and light chain genes by mye-
loid immune effector cells [18–20].
Traditionally, macrophages are divided into M1 and 
M2 categories. In the tumor milieu, M1 macrophages are 
typically tumor-suppressive and M2 macrophages serve 
an anti-inflammatory, tumor-supportive role [21]. The 
tumor-associated macrophages (TAM) play a key role in 
the host’s immune response to the tumor. Typically, TAM 
are attributed to promote tumor growth and progres-
sion in two different ways, directly by stimulating tumor 
cell proliferation and indirectly by creating an immuno-
suppressive microenvironment [22–26]. Moreover their 
infiltration is associated with a poor clinical outcome in 
cancer patients [27, 28]. But despite all these findings, 
the exact role of tumor-associated macrophages is still 
controversial.
Glioblastoma multiforme (GBM) is the most com-
mon malignant tumor of the central nervous system 
in adults with a global incidence of 0.59–3.69/100,000 
[29]. It is associated with poor prognosis and a median 
patient survival of 12–15 months from diagnosis [30, 31]. 
The long-term survival for glioblastoma patients, which 
is considered to be more than 3 years from diagnosis, is 
only at around 3–5% [32, 33]. Since GBM is rapidly fatal, 
therapy includes surgical resection to the extent feasible, 
adjuvant radiotherapy and temozolomide chemotherapy 
and is mostly only palliative [30, 34, 35].
Future prospects in the treatment of glioblastoma tend 
to immunotherapies or targeting of the tumor microenvi-
ronment. As the exact immunological features of TAM in 
glioblastoma is still unknown, we investigated the immu-
noglobulin repertoires of monocytes/macrophages in 
the tumor tissue and peripheral blood of 17 glioblastoma 
patients and compared them to the immunoglobulin rep-
ertoires of corresponding B cells. Detailed analyses of the 
immunoglobulin sequences are needed as these mye-
loid immunoglobulins might represent novel biological 
targets, since immunoglobulin variants are discussed as 
potential biomarkers and therapeutics in cancer [36].
In summary, the goal of this study is to determine 
whether patients with glioblastoma have a specific reper-
toire of myeloid antibodies, if there are differences in the 
immunoglobulin repertoires of circulating monocytes 
and tumor-associated macrophages from glioblastoma 
patients and if the myeloid antibodies can be a useful tool 
as therapeutic or diagnostic target in glioblastoma.
Materials and methods
Patient cohort
All 17 patients included in the study suffered from glio-
blastoma, which was assigned to WHO grade IV. After 
prior written consent, tumor tissue and peripheral blood 
for study purposes were obtained during surgery. The 
average age of the patients was 58 years with an age range 
from 43 to 74 years. An overview of the patient’s charac-
teristics is listed in Additional file 1: Table S1.
Cell isolation from tumor tissue/blood and purity control
Both the tissue and the blood samples were processed 
immediately after collection in the operating room. 
The fresh tumor tissue was manually divided into small 
pieces with a sterile single-use scalpel and enzymatically 
digested with a solution of DNase I (500 U/ml) and colla-
genase IV (190 U/ml) in RPMI at 37 °C and 5%  CO2 on a 
rotator for at least 90 min. Finally, the cell suspension was 
filtered and washed with PBS.
The blood sample was diluted 1:1 with PBS (Sigma 
Aldrich) and separated by density gradient centrifugation 
using Ficoll-Paque PLUS solution (GE Healthcare Life 
Sciences). The white layer of PBMCs was transferred to 
a fresh tube and washed with PBS. If necessary, one or 
two erythrocyte lysis steps followed. Subsequently, the 
cell suspensions from tumor and blood sample were sub-
jected to CD14 and CD19 Magnetic Cell Sorting (MACS, 
Miltenyi Biotec) to isolate monocytes/macrophages as 
well as B cells. The purified cell fractions were resus-
pended in 1  ml of TRIzol LS Reagent, respectively 
(Thermo Fisher). The purity of the isolated cell fractions 
was either tested by flow cytometry or the absence of B 
and T cells was demonstrated by using a highly sensitive 
PCR protocol.
Repertoire‑PCRs of immunoglobulins
For the analysis of gene expression, RNA was isolated 
according to the TRIzol LS Reagent manual by Thermo 
Fisher. cDNA synthesis was carried out using equal 
amounts of RNA to get comparable results in the fol-
lowing PCR. For every isolated cell fraction a quality 
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control PCR was conducted using primers for GAPDH, 
CD2, CD14, CD19, CD68 and CD163. Repertoire-PCRs 
for the desired immunoglobulins were performed for all 
cell fractions which passed the quality control. Depend-
ing on the studied antibody class, one reverse primer 
in the constant region of the specific immunoglobulin 
sequence and four to seven different consensus forward 
primers in the variable regions were used. In total, four 
antibody classes (IgM, IgG, Igκ, Igλ) were investigated. 
The sequences of the primers used in this study can be 
provided upon request.
Cloning and Sanger sequencing
For the generation of the immunoglobulin sequences, 
the PCR products were cloned into competent E. coli 
(Top10) by using the TOPO TA Cloning Kit for Sequenc-
ing (Thermo Fisher) according to the manufacturer’s 
protocol. The generated plasmids were purified out of 
liquid cultures using the GeneJET Plasmid Miniprep 
Kit (Thermo Fisher). Sequencing PCR was performed 
using the BigDye Terminator v1.1 Cycle Sequencing Kit 
(Thermo Fisher). The amplified sequencing-PCR-prod-
ucts were purified with the NucleoSEQ kit from Mach-
erey–Nagel and then used for Sanger sequencing on an 
ABI Prism 310.
Sequence analysis
For the analyses of the sequencing results the databases 
igBLAST and VBASE2 were used. All alignments, muta-
tion analyses and the construction of an own database 
were done using CLC Genomics Workbench by Qiagen.
Immunohistochemistry
CD14 immunostaining and HE staining of glioblastoma 
tissue was performed using standard protocols in the 
department of neuropathology of the university hospital 
Heidelberg. Analysis of the staining was conducted on 
an Olympus microscope IX70 with the camera “Progres 
Gryphax” by Jenoptik.
Cytokine release assay
The cytokine levels in the patient’s serum were analyzed 
using the Milliplex MAP Human Cytokine/Chemokine 
Magnetic Bead Panel (Merck Millipore). The patient 
samples and seven healthy controls were collected dur-
ing the study and stored at − 20 °C until the last patient 
was included. The assay was performed according the 
manufacturer’s protocol with the standards and quality 
controls in duplicates and all samples in triplicates. The 
plate was analyzed using the Milliplex Analyzer (Merck 
Millipore).
Quantitative volumetry of the tumors
All brain tumor volume measurements were performed 
using the iPlan Cranial Software 3.0.5 (Brainlab AG).
Statistical analysis
The student’s t-test was used to compare the significance 
of repertoire diversity, mutation rate and cytokine release 
between the different cell groups. *p > 0.05 and **p < 0.001 
was considered statistically significant. The Shannon 
diversity index is a mathematical tool to estimate vari-
ability of the immunoglobulin repertoires. It is expected 
that monoclonal and oligoclonal samples have low val-
ues, and highly diverse samples result in higher values 
[37, 38].
Results
High purity of the monocyte/macrophage cell preparations
Recent evidence revealed the expression of immuno-
globulins from macrophage subpopulations in the tumor 
microenvironment [20]. In this proof-of-principle study, 
different tumor entities were tested for the presence of 
the immunoglobulin expressing TAM subpopulation 
including one patient with glioblastoma. Here, we sys-
tematically investigated immunoglobulin repertoires of 
TAM from 17 glioblastoma patients (Additional file  1: 
Table  S1) and compared them to the circulating mono-
cytes of the same patients. To address this, we first estab-
lished a protocol for the reproducible isolation of  CD14+ 
cells from venous blood and tumor tissue. The purity 
of the isolated monocyte/macrophage populations was 
tested by flow cytometry. As these experiments showed 
a purity of > 99% the quality of the isolation method was 
confirmed (Fig. 1a). Using a highly sensitive quality con-
trol PCR protocol the isolated cell fractions routinely 
showed no characteristic gene expression of B and T cell 
markers (Fig.  1b, Additional file  1: Figure S1). Further-
more, the presence of the myeloid markers CD14, CD68 
and CD163 confirmed the isolated cells to be monocytes/
macrophages (Fig. 1b). Consequently, the highly pure iso-
lated cell fractions were used for further analysis of the 
immunoglobulin expression. Of note, expression of the 
secreted and membrane form of IgG could be identi-
fied in the monocyte/macrophage cell preparations from 
healthy individuals and glioblastoma patients (Additional 
file 1: Figure S2A).
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Higher immunoglobulin diversity in circulating monocytes 
than in the tumor‑associated macrophages
We analyzed the CDR3 heavy and light chain Ig reper-
toires expressed by TAM and monocytes obtained from 
15 patients with glioblastoma during surgery. In order 
to do this, the IgM, IgG, Igκ and Igλ repertoire diversi-
ties were determined by cloning and Sanger sequencing 
of the expressed Ig CDR3 variants. Peripheral blood B 
cells and B cells isolated form the tumor from three rep-
resentative glioblastoma patients (GBM003; GBM004; 
GBM008) were co-analyzed as reference. In total, 1293 
immunoglobulin sequences coding for 456 unique CDR3 
sequences were included in this study.
Hence, analysis of the immunoglobulin expression 
revealed diverse immunoglobulin heavy and light chain 
repertoires of monocytes and tumor-associated mac-
rophages in all glioblastoma patients. Interestingly, the 
immunoglobulin diversity between monocytes and B 
cells from the blood and macrophages isolated from 
the corresponding tumor sample of the same patient 
differed strongly (Additional file  1: Figure S3A). In all 
patients, the diversity of the expressed immunoglobu-
lins in the circulating monocytes was much higher than 
in the corresponding tumor-associated macrophages 
(Fig.  2, Additional file  1: Figure S4). Furthermore, the 
immunoglobulin expression level of circulating mono-
cytes was usually higher than in TAM (Additional 
file 1: Figure S2B). These results were also reflected by 
the Shannon Diversity Indices 0.95 for monocytes and 
0.42 for TAM (Additional file  1: Figure S3B). The size 
of the immunoglobulin repertoires from the circulat-
ing monocytes as well as the tumor-associated mac-
rophages of different patients was individual specific. 
Large variances from eighteen different immunoglobu-
lin heavy chain clonotypes in the circulating monocytes 
and only two different clonotypes in the tumor-asso-
ciated macrophages from one patient were found. A 
similar phenomenon could be identified in the immu-
noglobulin light chain repertoires (Fig.  2, Additional 
file 1: Figure S4).
Inter‑ and intra‑individual overlaps of immunoglobulin 
CDR3 variants
Most of the immunoglobulin CDR3 nucleotide 
sequences from TAM and monocytes (97.8% of all 
immunoglobulin heavy and light chain CDR3 variants) 
were found in only one subject. However, five immu-
noglobulin heavy chain CDR3-regions were found that 
were expressed in more than one patient (Table  1). In 
the B cell preparations from three representative GBM 
Fig. 1 Purity of the isolated CD14‑positive cells validated by flow cytometry and gene expression profiling. a Flow cytometry of freshly isolated 
MACS purified  CD14+ monocytes of one representatively chosen blood sample demonstrating purity of routinely 99.9% and absence of  CD19+/
CD22+ B cells. The analyses of PBMCs and  CD19+ B cells are shown as positive controls for the used antibodies. b RT‑PCR profiling is shown for 
 CD14+ monocytes from one representative healthy individual. Expression of GAPDH, B cell (CD19), T cell (CD2) and monocyte/macrophage marker 
genes (CD14, CD68, CD163) demonstrates the quality of the isolated cell preparations and the absence of detectable quantities of B or T cells. PBMC 
and  CD19+ B cells are demonstrated as reference. GAPDH glycerinaldehyd‑3‑phosphat‑dehydrogenase, PBMC peripheral blood mononuclear cells
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patients no CDR3 heavy chain sequences were shared 
between the different patients. However, we found two 
immunoglobulin heavy chain sequences in the B cell 
preparations shared between blood and tumor of the 
same patient (Additional file 1: Table S2). In the mono-
cytic cells, we found seven immunoglobulin heavy chain 
sequences in blood and tumor of the same patient. The 
immunoglobulin light chain sequences showed slightly 
more overlapping sequences in monocytes and TAM 
(ten CDR3 variants) as well as in the B cells (four CDR3 
variants) (Table 1 and Additional file 1: Table S2). Sum-
marizing, most of the myeloid immunoglobulin heavy 
and light chain sequences are individual specific but 
show a higher percentage of shared CDR3 variants than 
the B lymphocytic cells.
Diversity of the immunoglobulin repertoire 
from the tumor‑associated macrophage inversely 
correlates with the tumor volume
The diversity of the immunoglobulin repertoires in 
TAM and monocytes varied strongly between the indi-
vidual patients. The patient characteristics (tumor stage, 
IDH mutation, ARTX mutation, etc.) of the glioblas-
toma patients included in our study were quite uniform 
(Additional file 1: Table S1). However, one characteristic 
distinction between the single patients is their unique 
tumor volume which ranged from 3 to 92 ml.
Surprisingly, the diversities of the expressed immu-
noglobulin repertoires in TAM and monocytes, 
respectively, decrease with increasing tumor volume 
(Fig.  3a–d). The decrease of diversity with increasing 
tumor volume was more pronounced in monocytes. 
The inverse correlation is indicated by correlation 
coefficients between − 0.603 and − 0.977. Especially 
the light chains show a strong significant correlation 
with p = 0.029 for TAM and p = 0.014 for monocytes 
(Fig.  3c, d). Importantly, the number of  CD14+ cells 
isolated from the tumor and blood samples did not 
correlate with the tumor volume (Additional file  1: 
Figure S5), and histological analysis revealed an infil-
tration of a diverse number of  CD14+ cells in tumors 
of different sizes (Additional file 1: Figure S6). Of note, 
other patient characteristics showed no correlation 
with the immunoglobulin CDR3 repertoire of mono-
cytes and TAM (data not shown).
Contrasting to the immunoglobulin repertoire from 
macrophages, the immunoglobulin diversity from 
Fig. 2 TAM Ig heavy and light chain repertoires are less diverse than those of circulating monocytes. IgM and Igκ repertoire diversities in circulating 
monocytes and tumor macrophages from two representative patients (GBM001 and GBM003). Sector areas correspond to the relative frequency 
of individual clonotypes within a given Ig CDR3 repertoire and are sorted by size. Each sector within a circle chart represents a unique CDR3 variant 
and the total number of identified variants is shown in the center. Note that TAM express less diverse IgM and Igκ repertoires than monocytes from 
the same patients. The tumor volumes of the two patients are shown (11.3 ml and 74.9 mL, respectively). The repertoire diversities of all analyzed 
immunoglobulin sequences from all patients in this study are shown in (Additional file 1: Figure S4)
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B cells showed no correlation with the tumor size 
(Fig. 3e).
Immunoglobulin repertoire features of the CDR3 
sequences from myeloid cells and B cells
A detailed analysis of the myeloid and B cell immuno-
globulin repertoires was performed to investigate if the 
differences in immunoglobulin repertoire size between 
the cell populations are based on sequence specificities. 
Therefore, reference alignment and structural analysis of 
the immunoglobulin sequences of TAM and B cells from 
three representative patients provided detailed sequence 
information, such as the exact V gene and J gene usage 
and CDR3 length. Analysis of the immunoglobulin heavy 
and light chain CDR3 lengths from TAM and B cells var-
ied only slightly between TAM and B cells (Fig.  4a). As 
expected, the CDR3 sequences originating from B cells 
demonstrated Gaussian-type profiles. In contrast, the 
CDR3 length distribution in TAM showed a more oligo-
clonal profile in the three patients analyzed.
Additionally, the distribution of the sequenced 
 VH- and  JH-families was investigated. For this pur-
pose, the expressed IgM and IgG heavy chains of all 
glioblastoma-patients were summarized, grouped into 
families and compared to the corresponding B cells 
(Fig.  4b). Most of the expressed  VH-segments from 
tumor-associated macrophages and B cells (76% and 
68%, respectively) belong to the  VH3-family while the 
rest is equally distributed among the other five fami-
lies. The most used  JH-chains are  JH4 with 53% in mac-
rophages and 52% in B cells followed by  JH5 (21% and 
17%) and  JH6 (15% and 14%), respectively. This is in 
accordance with previously published numbers for nor-
mal B cells [39].
Thus, based on this analysis, we found that the dis-
tributions of immunoglobulin  VH- and  JH-family genes 
were comparable between B cells and TAM. Of note, the 
three most expressed  VH-genes in monocytes and TAM 
are 3-30-3*01 (64×), 3-21*01 (39×) and 3-33*01 (32×) 
whereas B cells expressed predominantly 3-33*01 (22×), 
6-1*01 (13×) and 3-11*01 (12×).
Analysis of the chromosomal localization of  VH‑region 
genes
Next, to assess whether the restriction of the immuno-
globulin repertoires in TAM had its origin in the locali-
zation of the  VH region genes on the chromosome,  VH 
region genes were mapped regarding to their chromo-
somal location for a comparative overview. The  VH region 
genes of the Ig heavy chains are located at the telomeric 
end of chromosomal band 14q32.33.
Fig. 3 Inverse correlation between the diversity of the immunoglobulin‑repertoire and the tumor volume. The total number of different 
immunoglobulin CDR3 variants from IgM‑ and IgG‑heavy chains expressed in tumor‑associated macrophages (a) and circulating monocytes (b) 
from glioblastoma patients is negatively correlated to the corresponding tumor volume. The inverse correlation of the total number of different 
CDR3 variants in tumor‑associated macrophages (c) and circulating monocytes (d) and the tumor volume was confirmed in the immunoglobulin 
light chain repertoires (Igκ‑ and Igλ). For all graphs (a–d) the respective correlation coefficients r and the p‑values are indicated. e The total 
number of different IgM and IgG CDR3 variants from tumor‑associated macrophages and B cells of three patients are shown. The immunoglobulin 
repertoires expressed by TAM show a higher repertoire diversity in the small tumor than in the large tumors. In contrast, the corresponding B cells of 
the same patients show a high repertoire diversity independent of the tumor volume
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The immunoglobulin repertoires of macrophages and 
B cells from three representative glioblastoma patients 
with a small, medium and large tumor were analyzed 
(GBM003, GBM004, GBM008; Fig. 4c). Here,  VH region 
genes expressed by B cells were widely distributed over 
the entire locus with different levels of expression as 
expected. In contrast, the  VH region genes expressed by 
TAM of the same patients were clustered in the center of 
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the locus. However, the clustering was less pronounced 
when immunoglobulin  VH region genes expressed by 
TAM and monocytes from all GBM patients analyzed in 
this study were taken into account (Additional file 1: Fig-
ure S7).
Similar mutation frequencies of immunoglobulin 
 VH‑Region genes expressed by tumor‑associated 
macrophages and B cells
Functional antibodies are assembled by V-(d)-J gene 
rearrangement and then diversified by somatic hyper-
mutation. The restricted immunoglobulin repertoire 
diversities in monocytes/macrophages compared to B 
cells prompted us to analyze the mutation frequencies of 
immunoglobulin  VH-region genes in macrophages and 
B cells. Therefore, the number of somatic mutations in 
macrophages as well as in B cells was quantified to exam-
ine if a lower number of somatic mutations provided an 
explanation for the smaller repertoire sizes. Interestingly, 
comparing the mutation frequencies of immunoglobu-
lin  VH region genes from TAM and the corresponding 
circulating monocytes revealed a higher mutation fre-
quency in TAM than in monocytes although they have 
a less diverse repertoire. This could be demonstrated for 
immunoglobulin heavy and light chain V region genes, 
respectively (Fig. 5a).
Of note, the overall number of mutations in the  VH 
region genes of IgM and IgG from macrophages and 
B cells showed a similar distribution for both cell types 
(Fig.  5b). But in general, the number of somatic muta-
tions in IgG sequences was significantly higher than in 
IgM sequences.
Thus, the differences in the immunoglobulin reper-
toire diversities between macrophages and B cells are not 
based on distinct abilities for somatic hypermutation.
Impaired immunocompetence of monocytic cells 
from GBM patients
GBM is described to be associated with systemic 
immune suppression [40]. In this regard, the immune 
status of the GBM patients was evaluated on the basis of 
cytokine release in the patients serum, HLA-DR expres-
sion of myeloid cells and hematological cell counts. The 
immune status was analyzed to examine if the restricted 
immunoglobulin repertoires might be based on impaired 
immunocompetence of the myeloid cell compartment. 
To test the overall immune status of the GBM patients 
in this study, serum cytokine levels of the GBM patients 
were compared to healthy controls. A number of pro-
inflammatory cytokines/chemokines including CCL2 
(MCP-1), CCL22 (MDC), sCD40L, CXCL10 (IP-10), 
CXCL8 (IL-8), EGF and CCL3 (MIP-1α) were (in some 
cases significantly) decreased in GBM patients compared 
to healthy controls suggesting a lowered immune com-
petence in GBM patients (Fig. 6, Additional file 1: Figure 
S8A). Most of these cytokines are primarily produced by 
monocytes/macrophages and may represent an impaired 
immune status of these myeloid cells. Interestingly, the 
anti-inflammatory cytokine IL-10 is increased in the 
glioblastoma patients which has already been reported 
in association with immunosuppression in glioblastoma 
[41], whereas TNFα serum levels were unaltered (Addi-
tional file 1: Figure S8B).
Hematological analyses in all patients revealed on 
average slightly elevated white blood cell counts with 
decreased lymphocyte, elevated neutrophil and normal 
monocyte cell counts (data not shown). These conditions 
have been previously described in glioblastoma patients 
[42].
HLA-DRA expression in monocytes has been 
described as a marker for immune competence. Espe-
cially in septic patients but also in the context of can-
cer, low HLA-DRA levels have been reported [40, 43]. 
A tendency to lower HLA-DRA expression in mono-
cytic cells especially of TAM from GBM patients in 
this study compared to expression levels in monocytes 
from healthy individuals are demonstrated (Additional 
file  1: Figure S9). Consequently, several evidences for 
impaired immunocompetence of immune cells espe-
cially monocytes in the glioblastoma patients are 
detected and which are not based on decreased num-
bers of monocytes in the peripheral blood.
(See figure on previous page.)
Fig. 4 Immunoglobulin repertoire features of macrophages and B cells. a The immunoglobulin heavy (left) and light chain (right) CDR3‑length 
distributions are shown for the investigated tumor‑associated macrophages and B cells from three representative patients. The number of 
nucleotides of the respective CDR3 sequence length (nt, x‑axis) is plotted against the frequency of the respective CDR3 sequence length (n, y‑axis). 
n = total number; nt = nucleotide. b The  VH‑ and  JH‑family gene usage by TAM and B cells are indicated. The frequency (in %) of  VH family genes (left) 
and  JH‑family genes (right) expressed by TAM and B cells, respectively, from three representative glioblastoma patients demonstrate a similar genes 
usages in both cell groups. c Distribution of the expressed V‑chain genes of tumor‑associated macrophages and B cells from three representative 
glioblastoma patients on the immunoglobulin heavy chain locus of chromosome 14. Here, macrophages show a restricted distribution with focus 
in the center of the locus compared to B cells which express more widely distributed V‑chains. The distribution of all V chain genes expressed by 
TAM analyzed in this study is shown in Additional file 1: Figure S7
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Discussion
Glioblastoma multiforme is the most common brain 
tumor in adults that is characterized by a marked het-
erogeneity at the cellular and molecular level [44]. In 
GBM, tumor-infiltrating microglia and peripheral mac-
rophages are major immune cell populations within the 
tumor accounting for up to 30% of tumor mass in human 
GBMs [45]. In a recent study, we presented the expres-
sion of recombined immunoglobulin heavy and light 
chains in tumor-associated macrophages isolated from 
various types of tumor tissue [20]. In the present study, 
we were able to show, for the first time, the constitutive 
expression of immunoglobulin heavy and light chains in 
tumor-associated macrophages and circulating mono-
cytes in a cohort of glioblastoma patients. Of note, the 
soluble and the transmembrane forms of immunoglobu-
lins were demonstrated in monocytes and macrophages.
Importantly, highly diverse and individual-specific 
immunoglobulin heavy and light chain repertoires 
were detected in the circulating monocytes and in 
macrophages from tumor tissue of all 15 glioblastoma 
patients analyzed in this study. However, the immu-
noglobulin repertoire diversity in the myeloid cells 
was highly restricted compared to the B cells of three 
Fig. 5 Mutation frequencies in tumor‑associated macrophages and circulating monocytes. a The mutation frequencies (× 10−3) of the heavy 
chains IgM and IgG as well as the light chains Igκ and Igλ of tumor‑associated macrophages and circulating monocytes are demonstrated. For 
all four Ig classes higher mutation rates were found in TAM than in circulating monocytes. The mutation frequencies were clustered in different 
categories depending on the number of mutations per  VH region gene (0; 0.1–20; 20.1–40; > 40). b The overall mutation frequencies of IgM and IgG 
heavy chains in monocytes/macrophages and B cells are shown. The investigated tumor‑associated macrophages and circulating monocytes show 
the same distribution of mutations as their corresponding B cells. In all investigated cell types, the mutation frequency for IgG is significantly higher 
(p > 0.01) than for IgM
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representative patients. This is in accordance with pre-
vious reports about restricted variable immunoglobu-
lin and T cell receptor repertoire expression in myeloid 
cells [9, 17, 18, 20]. Of note, all sequences in this study 
were generated by cloning and Sanger sequencing of PCR 
products generated with consensus primers. A primer 
bias could be ruled out due to the significant differences 
of the expressed  VH genes between the myeloid and B cell 
populations. Moreover, the number of somatic mutations 
within the immunoglobulin sequences, the chromosomal 
localization of the expressed  VH-genes, the CDR3 length, 
and the use of  VH and  JH chain-family genes did not show 
significant differences between monocytes/macrophages 
and the B lymphocytic cells. This suggests a pathway of 
recombination of the individual immunoglobulin gene 
segments in the myeloid cells which is very similar or 
even identical to the mechanism used in B cells.
In addition to the lower immunoglobulin diversity 
in TAM and monocytes compared to B cells, we were 
able to demonstrate an inverse correlation of the immu-
noglobulin repertoires with the respective individual 
tumor size of the GBM patients. For the investigated 
light chains this inverse correlation was statistically sig-
nificant (p = 0.029 and p = 0.014), while the significance 
level of 5% was missed for the heavy chains in both cases. 
In the future, by extending the patient population and 
using a high-throughput sequencing approach, how-
ever, statistical significance will probably be achieved. 
The inverse correlation was specific for the myeloid cell 
compartment and could not be detected in B cells. In 
the tumor microenvironment, infiltrating macrophages 
have been described as antitumor M1 as well as protu-
moral M2 phenotypes [23]. These functional phenotypes 
are defined by differential expression of surface markers, 
secreted cytokines, and roles in immunoregulation [45]. 
However, clinical and mouse model data correlate the 
accumulation of macrophages with protumoral activi-
ties [22–25]. Due to the negative dependence of antibody 
diversity and tumor size, an immunosuppressive effect 
of the tumor and its microenvironment on the immuno-
globulin-expressing macrophages and monocytes might 
be conceivable. Larger tumors seem to have stronger 
suppressive effects on the immunoglobulin expression 
of myeloid cells than smaller tumors. Importantly, the 
suppressive effect seems to be more pronounced within 
the tumor than in the periphery. The observed lowered 
cytokine release and lowered HLA-DR expression of 
monocytic cells in the GBM patients are in line with this 
hypothesis. Impaired immunocompetence on the level of 
cytokine release and other features have been reported in 
several studies of glioblastoma [46, 47].
On the other hand, an alternative explanation for our 
results showing even more restricted immunoglobulin 
repertoires in the TAM compartment than in the circu-
lating monocytes might be conceivable. Similar results 
were obtained in studies where variable immune 
receptors of tumor-infiltrating lymphocytes (TIL) 
were compared to circulating lymphocytes [48, 49]. 
These studies showed a clonal restriction due to oli-
goclonal expansion in the TIL compartment suggest-
ing an adaptation to- or a modification by the tumor 
microenvironment. Mohme et  al. conclude that TIL 
have undergone antigen-induced activation and should 
be able to mount a cytotoxic anti-tumor response [49]. 
Correspondingly, due to the limited immunoglobulin 
diversity in TAM a tumor-specific selection of TAM 
leading to specific immunoglobulin expression could 
be reasonable. In line with this is the high frequency of 
Fig. 6 Serum levels of cytokines in healthy individuals and GBM patients. Serum levels of CCL22 (MDC, left) and CCL2 (MCP‑1, right) from healthy 
controls (n = 7) and GBM patients (n = 11) are shown. The cytokine concentrations were measured from serum samples with an multiplex Luminex 
assays in triplicates. *p < 0.05; **p < 0.001. The serum levels of additional cytokines are shown in Additional file 1: Figure S8
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somatic mutations in the variable regions which indi-
cates that the tumor-infiltrating macrophages locally 
produce restricted immunoglobulin repertoires with 
evidence of antigen-driven maturation. It might there-
fore be possible that the immunoglobulins expressed 
by TAM are implicated in the anti-tumor immune 
response. Conceivably, the restricted antigen-specific 
immunoglobulin variants expressed by the monocytic 
lineage could be a useful as diagnostic or therapeutic 
target. Indicative for this is that a more detailed analy-
sis of the macrophage immunoglobulin repertoires 
revealed that the expressed immunoglobulin CDR3 
variants show intra-individual overlaps between the 
peripheral blood and tumor compartment, as well as 
inter-individual overlaps of the repertoires between 
several patients. Interestingly, in almost half the 
patients we find shared immunoglobulin CDR3 vari-
ants between circulating monocytes and tumor-asso-
ciated macrophages isolated from the same patients 
suggesting a migration of monocytes expressing spe-
cific CDR3 variants to the tumor microenvironment 
and selection in situ. This is in accordance with a cur-
rent study showing that 85% of the TAM population 
in glioma are comprised of infiltrating monocytes and 
macrophages [50]. It might be conceivable that even 
more patients show shared CDR3 variants between 
the blood and tumor compartment with a more sensi-
tive NGS-based repertoire analysis method. To analyze 
this aspect in more detail, a study using RACE-PCR 
and NGS for glioblastoma patients in comparison to 
healthy controls is currently undertaken in our labora-
tories. Furthermore, the shared immunoglobulin vari-
ants represent interesting target molecules and will be 
investigated in the future.
So far, the phenotype of the  CD14+ immunoglobulin 
expressing macrophages (M1 or M2 category) is ambigu-
ous and further analyses including single-cell transcrip-
tomics in combination with immune receptor profiling 
are urgently needed to characterize this specific sub-
population in more detail. Moreover, investigation of 
the antigen specificity of the myeloid immunoglobulins 
will help to further uncover the role of tumor-associated 
macrophages in glioblastoma. Since TAM are discussed 
as potential targets in glioblastoma therapy [51], immu-
noglobulins expressed by TAM might have an impact on 
future therapeutic approaches.
In conclusion, the expression of variable immunoglob-
ulins in monocytes and TAM can be a useful tool for the 
characterization of the tumor-infiltrating myeloid cells, 
as a therapeutic target or as a diagnostic marker for glio-
blastoma patients.
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